Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: A randomized controlled trial

JAMA

Volumn 292, Issue 2, 2004, Pages 202-209

  Taha, Taha E ^a   Kumwenda, Newton I ^a   Hoover, Donald R ^b   Fiscus, Susan A ^c   Kafulafula, George ^d   Nkhoma, Chiwawa ^e   Nour, Samah ^a   Chen, Shu ^a   Liomba, George ^d   Miotti, Paolo G ^f   Broadhead, Robin L ^d  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MALAWI   (Malawi)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; NEVIRAPINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; BREAST FEEDING; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; LIFE TABLE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALAWI; MALNUTRITION; MONOTHERAPY; MOUTH LESION; OPEN STUDY; PERINATAL INFECTION; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SEPSIS; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; VIRUS LOAD; VIRUS TRANSMISSION; DELIVERY; DISEASE TRANSMISSION; DRUG COMBINATION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; MULTICENTER STUDY; NEWBORN; PHASE 3 CLINICAL TRIAL; PREGNANCY; PREGNANCY COMPLICATION; SERODIAGNOSIS; SURVIVAL;

ADULT; AIDS SERODIAGNOSIS; ANTI-HIV AGENTS; DELIVERY, OBSTETRIC; DISEASE TRANSMISSION, VERTICAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; MALAWI; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; SURVIVAL ANALYSIS; VIRAL LOAD; ZIDOVUDINE;

EID: 3042848856     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.2.202     Document Type: Article

References (31)

1. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda. Lancet. 1999; 354:795-802.
2. Dabis F, Msellati P, Meda N, et al. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso. Lancet. 1999;353:786-792.
3. Wiktor SZ, Ekpini E, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire. Lancet. 1999;353:781-785.
4. Mirochnick M, Fenton T, Gagnier P, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. J Infect Dis. 1998;178:368-374.
5. Mirochnick M, Siminski S, Fenton T, et al. Nevirapine pharmacokinetics in pregnant women and in infants after in utero exposure. Pediatr Infect Dis J. 2001; 20:803-805.
6. Lallemant M, Jourdain G, Le Coeur S, et al. Multicentre, Randomized Controlled Trial, Assessing the Safety and Efficacy of Nevirapine in Addition to Zidovudine for the Prevention of Perinatal HIV in Thailand: The Second IAS Conference on HIV Pathogenesis and Treatment, Paris, France, 13-16 July 2003. London, England: International Medical Press; 2003.
7. Centers for Disease Control and Prevention. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR Morb Mortal Wkly Rep. 1998;47:22-23.
8. Nolan M, Fowler MG, Mofenson LM. Antiretroviral prophylaxis of perinatal HIV-1 transmission and the potential impact of antiretroviral resistance. J Acquir Immune Defic Syndr. 2002;30:216-229.
9. Martinson N, Morris L, Gray G, et al. HIV resistance and transmission following single-dose nevirapine in a PMTCT cohort. In: 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco, Calif. Abstract 38.
10. Kourtis AP, Bulterys M, Nesheim SR, Lee FK. Understanding the timing of HIV transmission from mother infant. JAMA. 2001;285:709-712.
11. Mirochnick M. Antiretroviral pharmacology in pregnant women and their newborns. Ann N Y Acad Sci. 2000;918:287-297.
12. Musoke P, Guay LA, Bagenda D, et al. A phase I study of the safety and pharmacokinetics of nevirapine in HIV-1 infected pregnant women and their neonates. AIDS. 1999;13:479-486.
13. Taha TE, Kumwenda NI, Gibbons A, et al. Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1. Lancet. 2003;362:1171-1177.
14. Mirochnick M, Dorenbaum A, Blanchard S, et al. Pre-dose infant nevirapine (NVP) concentration with the 2-dose intrapartum-infant NVP regimen. In: 3rd Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants; September 9-13, 2001; Kampala, Uganda. Abstract 101.
15. UNAIDS/WHO: Working Group on Global HIV/AIDS/STI Surveillance. Guidelines for using HIV testing technologies in surveillance. Available at: http://www.who.int/hiv/pub/surveillance/en/ guidelinesforUsingHIVTestingTechs_Epdf. Assessibility verified June 10, 2004.
16. Biggar RJ, Miley W, Miotti P, et al. Blood collection on filter paper: a practical approach to sample collection for studies of perinatal HIV transmission. J Acquir Immune Defic Syndr. 1997;14:368-373.
17. Taha TE, Kumwenda N, Gibbons A, et al. Effect of HIV-1 antiretroviral prophylaxis on hepatic and hematological parameters of African infants. AIDS. 2002; 16:851-858.
18. Division of AIDS (DAIDS) Toxicity Table for Grading Severity of Pediatric (≤3 Months of Age) Adverse Experiences. Available at: http://www/hptn.org/ Web%20Documents/Regulatory_Resources/PediatricToxTablesLessthan3months.pdf. Accessibility verified June 4, 2004.
19. Chiang CL. The Life Table and Its Applications. Malabar, Fla: Robert E. Kreiger Publishing Co; 1984:156.
20. Greenwood M. The Errors of Sampling of the Survivorship Tables. London, England: Her Majesty's Stationery Office; 1926. Reports on Public Health and Statistical Subjects, No. 33.
21. Szklo M, Nieto FJ. Epidemiology: Beyond the Basics. Gaithersburg, Md: Aspen Publishers Inc; 2000: 434.
22. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda. Lancet. 2003;362:859-868.
23. Moodley D, Moodley J, Coovadia H, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis. 2003;187:725-735.
24. The PETRA Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (PETRA study). Lancet. 2002;359:1178-1186.
25. Beckerman KP. Long-term findings of HIVNET 012. Lancet. 2003;362:842-843.
26. Dorenbaum A, Cunningham CK, Gelber RD, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission. JAMA. 2002;288:189-198.
27. Gailiard P, Fowler MG, Dabis F, et al. Use of antiretroviral drugs to prevent HIV-1 transmission through breastfeeding. J Acquir Immune Defic Syndr. 2004; 35:178-187.
28. Boucher FD, Modlin JF, Weller S, et al. Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. J Pediatr. 1993;122:137-144.
29. Biggar RJ, Miotti PG, Taha TE, et al. Perinatal intervention trial in Africa: effect of a birth canal cleansing intervention to prevent HIV transmission. Lancet. 1996;347:1647-1650.
30. Semba RD, Kumwenda NI, Hoover R, et al. Human immunodeficiency virus load in breastmilk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis. 1999;180: 93-98.
31. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1 -infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Available at: http:www.aidsinfo.nih .gov. Accessibility verified June 4, 2004.